Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bhag Karamchandani who wrote (4368)	5/21/1998 11:36:00 PM
From: George T. Santamaria	Read Replies (1) of 6136

<On the other hand, as I have noted before, AGPH has spent hundreds of millions of dollars on R & D over seven years (?) and has yet to bring an in-house designed drug to market. Let us hope AG 3340 fares better than Thymatiq. Hope someone can explain why. It may be comforting to AGPH longs. Cheers. > If you are not willing to give AGPH credit for designing the drug in house, then tell me, what value do you give to the organization that designed the drug but did not appreciate it's potential enough to take it commercial??

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next